Trial Profile
An Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of Omecamtiv Mecarbil Administered Orally to Patients With Stable Heart Failure
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2021
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Cytokinetics
- 27 May 2011 Planned end date changed from 1 Oct 2011 to 1 May 2011 as reported by ClinicalTrials.gov
- 27 May 2011 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov
- 30 Sep 2010 Planned end date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.